Podcasts about endeavor

This is our endeavor. To blade! To tongue! To plow! To grind our name into the bones of tomorrow, until the horizon is lucid smooth as liquid mirror, sharp as cut glass, clear as cool water rising, Irrigating in our throats the dry river bed of ambition. A witch in the gut of the tower. A wild one embraced by blood. A wizard in the court of the sword. All days divided into the days before and the days after, like the two sides of a shut window of black glass. We are:Brennan Lee MulliganErika IshiiAabria IyengarLou Wilsonand is produced, designed, and scored by Taylor Moore at Fortunate Horse with exquisite design and editing help from Jared OlsonSPECIAL THANKS TO: Shannon and Amanda Freberg! Transcript of this episode coming soon! You can find transcripts of all our episodes here, for free, on our Patreon. We're a little behind, but we're gonna catch up!Our album art is by the great Corey BrickleySome additional environmental sound design comes from Michael Ghelfi Studios. You can get their sounds and music for your home games and VTT as well, which we enthusiastically recommend. 

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including CMLL, AAA, AEW, Max, NWA, Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Greg and Cathy Buffkin join me on the podcast today to share the story of their son Ryan—a funny and tenderhearted young man who brought joy and laughter to everyone around him. As we get to know Ryan through their memories, we also learn about the hidden struggles he carried and the heartbreaking loss they experienced when he died by suicide in the fall of 2015.With honesty and grace, Greg and Cathy open up about the complicated grief that comes with suicide loss, including the misconceptions that often surround it. They speak directly to the false belief that suicide is the unforgivable sin, offering reassurance that Ryan knew the Lord and is with Him now. Our conversation is both tender and powerful, offering hope, truth, and the comforting reminder that God's love never lets go—even in our deepest sorrow.In this conversation, you'll hear:Stories of Ryan's life and personalityThe events leading up to his deathThe discovery of deeply painful truths after his passingHow Greg and Kathy have processed their grief over the past ten yearsThe impact of sibling loss on their surviving daughterGentle, faith-filled advice for parents grieving a suicideA reminder that God's love reaches even into our darkest placesThis episode is tender, honest, and full of hope. If you've lost a child—or know someone who has—Greg and Cathy's story will remind you that you are not alone and that God is present, even in the pain.Resources & Links:While We're Waiting – Support for bereaved parentsScripture References:Romans 8:1 – “There is therefore now no condemnation for those who are in Christ Jesus.”Romans 8:38-39 – “Nothing in all creation will be able to separate us from the love of God in Christ Jesus our Lord.”Romans 8:28 – “And we know that in all things God works for the good of those who love him…”Connect with Us:Subscribe to the podcast so you never miss an episodeLeave a review to help others find hopeVisit whilewerewaiting.org to learn more about our ministry for bereaved parentsCome back next week to hear the rest of the Buffkins' storyI would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry. We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at: jill@whilewerewaiting.org

**REPEAT EPISODE*** So good I had to say it again… Sun Tzu was a Chinese general, military strategist, writer, and philosopher who lived in the Eastern Zhou period of ancient China. Sun Tzu stresses the importance of knowing one's own strengths and weaknesses, as well as those of the enemy, to gain a strategic advantage.  Avoiding Unnecessary Conflict: A core principle is to avoid battle whenever possible, seeking to subdue the enemy through diplomacy or other means before resorting to direct confrontation.   • Psychological Warfare:  Involves manipulating the enemy's perception and actions, not engaging in personal attacks or pettiness.  I am NOT a communist sympathizer, but China got the scratch to be about that life… ***China seems to think the US wants the smoke, so China is like... bring it. I hope it is true that while they leave the MAGA trade negotiators on read, China is playing Obama speeches…I want this to be true #pettylujah Ms. Tina Knowles Lives Woke... From Weeks Island, LA with Love Ms. Tina K. 432 pages of T—still elegant proud not stooped or bent…hearing Ms. Tina read her own words still can't replace the actual book which I will be ordering….   Reading the book or listening on Audible...you do need both in your life.... From Weeks Island to Seaside Malibu—The fire that destroyed her  home in Malibu was similar to the fire bombing that propelled her family from Weeks Island, a former plantation/salt mine, to Galveston. Still can be bound and have to be re-educated- Sewing bartered skill but only limited by your own fear, mother life of anxiety/fear rightfully so, but binding that she had to unlearn so much. Possibility to fiercely love a parent, admit that they were wrong in a lot, but still love them. The nuns in charge of the children for decades exacted vengeance and sought to humiliate and shame them out of childhood…I would have snatched that tramp's bonnet like President Biden's mama the first time she threatened or hit my kid…chile. The T-on reality TV and Pop Culture Unless you have personal video of ish being removed and returned from the Black-sonian I'm going to need you to have a seat and shut up co trolling my cortisol so should you   Weird loud white conservative making rules. And a bunch of people climbing out of their families basements and thinking you can talk crazy to people. Have seat. We all should be afraid Is it Mormon Tock or Mom tock…Sister Wives Poly Family ya'll Don't even watch TV dictating my viewing da fuck   Lock up Ky creativity and depravity   Go to your prayer closet and leave me alone #rhoa I am a Reigndrop love Monday Live recaps descent to mean girl…season 7 Porsha a mean girl dragged Kenya friend of… she literally still the same selfish airhead now. Claudia clocked it standing on business Trauma bonding 11 seasons still gutta Shame her into act right does what necessary to elevate her brand Season 7 reunion friend of Season 8 Shade Assasin Kenya deprived of us of good ol fashion Read…Regine perfect HW—Kim Fields(wanted to be regular and she was not)  not so much.  Friend of —Sharee Not even the fun Tee Tee. Porsha and single Shamea caught up in some -ish, Miami Season 9 Apex of Frick and Frack, Phaedra exits to return Season 16. If Phaedra going to be fake, not interested.  Contact Us on: https://linktr.ee/tnfroisreading Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, comments on the show, or suggestions for Far From Beale St additions.  

Just because something happens at the start doesn't mean it will happen forever.

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including AEW on Max Ratings, NWA deal with Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

INTRO (00:23): Kathleen opens the show drinking a Lager For The Lakes American Lager from Bell's Brewing in Kalamazoo, MI. She reviews her weekend with family in Missouri, playing with her sister's dog and grilling for her brother-in-law on Father's Day.    TOUR NEWS: See Kathleen live on her “Day Drinking Tour.”   COURT NEWS (18:13): Kathleen shares news announcing that Dolly's new Nashville hotel will open Spring 2026, Post Malone & Jelly Roll cause a giant traffic jam in Southern Missouri, Stevie Nicks releases new Fall concert dates, and Cher's son Eligah is hospitalized again.    TASTING MENU (2:33): Kathleen samples Lesser Evil Organic Cheddar Popcorn, Lay's Wavy Magic Masala chips, Hidden Valley Jalapeno Ranch dressing, and Weber Grilling Fireball whiskey flavored seasoning.    UPDATES (23:44): Kathleen shares updates on Baby Reindeer's Fiona Harvey, the Florida Panthers win the 2025 Stanley Cup, the first Millennial saint gets his canonization date, Brooke Shields' podcast interview criticizing Meghan Markle quietly disappears, a Kentucky man is arrested for releasing a raccoon in a bar, and the 2025 NBA Finals ratings are the lowest in 27 years.   HOLY SHIT THEY FOUND IT (42:43): Kathleen reveals that Oklahoma is now producing Mountain Lions, and Captain James Cook's lost ship “The Endeavor” has been found in a Rhode Island harbor.    FRONT PAGE PUB NEWS (57:13) : Kathleen shares articles on the Louvre staff shutting the museum to protest overuse, the Bonnaroo Music Festival is cancelled due to extreme weather, Anderson Cooper's CNN contract is up for renewal, the 10,000-step exercise concept is derived from “Japanese Walking,” Red Lobster unveils a new menu, the Beach Boys' Brian Wilson dies aged 82, Country Music just got a Grammy update, Atlanta could get another NHL team, and the best fast food French fries are revealed.   STUPID TOURIST STORIES (46:25): Kathleen reads about a New Jersey tourist who is gored by a bison in Yellowstone, and a tourist crushes a priceless Van Gogh chair while taking a photo.    SAINT OF THE WEEK (1:19:22): Kathleen reads about Saint Fiacre.     WHAT ARE WE WATCHING (37:13): Kathleen recommends skipping “The Mortician” on Max, and “Titan: The OceanGate Disaster” on Netflix.   

Keith Friedenberg serves as Chief Analytics & Insights Officer of Endeavor Group Holdings, Inc. which owns and operates Ultimate Fighting Championship (UFC), World Wrestling Entertainment (WWE), William Morris Endeavor (WME), IMG, 160over90, On Location, and OpenBet/IMG Arena. Keith is founder of Endeavor Analytics, LLC, a global knowledge and insights company that provides strategic consulting, media intelligence, valuation services, and consumer insights. Endeavor Analytics boasts a global team of 80 who leverage AI & machine learning and third-party data providers to inform decision-making across media & sports properties, talent & athletes, and Fortune 500 brands. Prior to joining Endeavor in 2008, Friedenberg spent eleven years with Warner Bros. Media Research & Insights, where he supervised consumer, media and brand research operations for divisions including domestic television distribution, gaming, consumer products and emerging technology. Keith is an alumnus of the Marshall School of Business, University of Southern California.

Preparing students for tomorrow's workforce takes more than strong academics; it takes all of us working together to equip them with skills for success.From classrooms to community partners, every role matters. Today's episode explores how schools, families, and businesses can team up to build a career-ready future for every graduate.#EducationalLeader,Kim “When students are led well, they learn well.”Website: http://kimdmoore.comBook: http://leadershipchairbook.comLinkedIn: https://linkedin.com/in/kimdmooreYouTube: https://youtube.com/@EducationalLeaderThe views shared in the Educational Leadership Moment are solely mine and do not reflect the positions of my employer or any entity within the local, state, or federal government sectors.

Ben, Paul, and Trey discuss first impressions of two big games: Moon Colony Bloodbath and Endeavor Deep Sea. Somehow, we all got mad at each other in each game. Fun!We also chat about recent game plays of Dune Imperium and Wavelength, and extra bonus: the return of Games on the Brain!00:00 Intro00:57 Game Rooms08:05 Dune Imperium21:44 Wavelength33:49 Ito41:37 Landmarks of the Lost Atlas51:40 Oranges & Lemons53:00 Barcelona: The Rose of Fire54:06 Cargo Empire01:03:11 Moon Colony Bloodbath01:34:51 Endeavor Deep Sea

I'm back this week with four more shipwreck stories. We'll start with the horrific explosion of the Mississippi river steamboat, the Sultana in 1865. Next, we'll tackle the Titanic which famously sank in 1912, killing around 1,500 passengers. On to another famous ship, the Endeavor. The Endeavor was the British naval ship used by explorer Captain James Cook during his first voyage of discovery which landed him in Australia, New Zealand, and Tahiti in the mid 1700s. Later the ship changed hands and was eventually used and intentionally sunk during the American Revolutionary War. Finally, I'll end with what is, quite possibly, one of the most controversial shipwrecks ever found, the San Jose. This Spanish galleon has been called the "holy grail" of shipwrecks because it was supposedly carrying treasure worth up to 17 billion dollars today when it went down in 1708. As five plus countries argue over the San Jose's treasure, the ethical question remains - what should be done with these shipwrecks?Support the show! Join the Patreon (patreon.com/historyfixpodcast)Buy some merchBuy Me a CoffeeVenmo @Shea-LaFountaineSources: American Battlefield Trust "The Sultana Disaster"Wikipedia "Sultana"New York Times "Civil War Hull Is Reported Found"Live Science "Digital "resurrection" of the Titanic sheds light on fateful night the ship tore apart"National Geographic Press Release "National Geographic reveals groundbreaking underwater scan..."The Times "At last, the Titanic wreck is left to rust in peace"Wikipedia "James Cook"Australian National Maritime Museum "Evidence Identifying Endeavor"The Guardian "Discovery provides further evidence shipwreck is Captain Cook's Endeavor, maritime scientists say"The Guardian "Worm-eaten shipwreck of Captain Cook's Endeavor under threat from more marine animals"BBC "The fierce battle over over the 'Holy Grail' of shipwrecks"Shoot me a message!

Spieleindrücke - Keksekästchen - Schattentheater - Kauri - Endeavor - Weimar

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including R Truth, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

On this episode of The Digital Patient, Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, and colleague, Alan Sardana, chat with Justin Brueck, System Vice President of Innovation and Research at Endeavor Health, about "the Business Case for AI Scribes, Rethinking Care Delivery from First Principles to Solve for The Silver Tsunami, Embedding Genomics into Patient Care, and more..."

This week Shelley and I check out the SECOND of the Kennerspiel des Jahres nominees: Endeavor: Deep Sea by Carl de Visser and Jarratt Gray from Burnt Island Games and Grand Gamers Guild then have fun with a bunch of short-legged dogs in Clash of Corgis, a self-published game from Deric Drazich Thanks as always to our sponsor Bezier Games! You can support the podcast directly by becoming a sponsor www.patreon.com/garrettsgames OR you can check out our estensive list of games that no longer fit on our shelves, but belong on your table: https://docs.google.com/spreadsheets/d/16ovRDNBqur0RiAzgFAfI0tYYnjlJ68hoHyHffU7ZDWk/edit?usp=sharing

Feds blast 'Sisyphean endeavor' aim to pull back $4 billion for California High Speed Rail Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

This week on The Bludd Drop, the newest weekly segment of The Snug Wrestling Podcast, Mr. Bludd takes a deep dive into WWE's ongoing transformation in what many are calling the "Corporate Era" under TKO. Since WWE's high-profile merger with Endeavor a few years back, the company has been reshaping its identity, navigating major shifts in management, talent relations, and the overall product. Is this new era a step forward or a sign of something bigger brewing behind the scenes? Mr. Bludd shares his raw and unfiltered thoughts on the state of WWE today—don't miss it!Tune in now, and be sure to leave a star rating and review!

Feds blast 'Sisyphean endeavor' aim to pull back $4 billion for California High Speed Rail Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

What do bluegrass, bourbon, and Bible have in common? How about a group of Hillbilly Thomists? Today, we share an episode from the Signal Award-winning podcast, No Small Endeavor. Produced by PRX and Great Feeling Studios, No Small Endeavor explores what it means to live a good life.In this episode, you'll hear from the Hillbilly Thomists, the Billboard-charting bluegrass band made up entirely of Catholic Dominican Friars. They talk about their theology and vocation, as well as how they manage life on the road as priests who have taken a vow of poverty. Plus, they give live performances of some of their finest songs.When they are not contemplating, studying, and preaching, the Hillbilly Thomists are writing songs. They've released four albums includingHillbilly Thomists, Living for the Other Side, Holy Ghost Power, andMarigold. Marigold spent 3 weeks on the Billboard bluegrass charts, debuting at #2. The friars also have a Christmas album in the works.Proceeds from album sales, donations, and merchandise sales allow the friars to continue to produce and perform music, while providing ongoing support to the formation of friars at the Dominican House of Studies in Washington, D.C.Thanks to No Small Endeavor for sharing this episode with us.For other episodes like this one, follow No Small Endeavor on Apple Podcasts, Spotify or your favorite podcast app.Learn more about the Hillbilly ThomistsLearn more about No Small EndeavorAttend a Living Church conferenceGive to support this podcast

In our annual Spiel des Jahres special shows Ben talks to the nominees. This time it's the Kenner Spiel des Jahres  with Ben having a chat with Carl de Visser and Jarrat Gray about the game's development and their hopes for the award.Support the show hereBecome a supporter of this podcast: https://www.spreaker.com/podcast/five-games-for-doomsday--5631121/support.

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including Real American Wrestling, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Get 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

What does it mean to lead legal operations when there's no clear blueprint?In this episode of The Abstract, host Tyler Finn sits down with Adam Becker, Director of Legal Operations at Cockroach Labs and board member at CLOC, for a candid conversation about evolving careers, scaling legal departments, and the growing scope of legal ops. From breaking the “lawyer mold” to embracing AI-native strategies, Adam shares personal lessons on confidence, curiosity, leadership, and why legal ops is entering a new season of strategic impact.The discussion also explores how CLOC's community and resources help elevate the field, and why every legal ops professional should see themselves as a partner to the GC — not just a process owner.Read detailed summary: https://www.spotdraft.com/podcast/episode-101 Topics Introduction and career arc overview: 0:00 Early clues that pointed to process thinking: 1:14Breaking out of the lawyer mold and recognizing transferable skills: 2:09Confidence, curiosity, and pivoting into legal ops: 5:51Driving impact at MetLife and Endeavor: 8:33 Why legal ops requires conviction, not just thick skin: 11:09 The people-process-tech triangle — and why “people” matters more: 14:13 Culture and collaboration at Cockroach Labs: 16:36Balancing scale with flexibility in a fast-growing company: 18:53How legal ops has evolved through CLOC's growth: 21:14Is legal ops at a crossroads? And what's CLOC's role in the future?: 26:22Rapid Fire: 32:59Connect with us: Adam Becker - https://www.linkedin.com/in/adam-becker-896a7a3/ Tyler Finn - https://www.linkedin.com/in/tylerhfinn SpotDraft - https://www.linkedin.com/company/spotdraft SpotDraft is a leading contract lifecycle management platform that solves your end-to-end contract management issues.Visit https://www.spotdraft.com to learn more.

Dan Patriss is here to share the latest news from the board game world! Subscribe to the Major Spoilers Podcast Network Master Feed! Major Spoilers Podcast Network Master Feed RSS Feed Show your thanks to Major Spoilers for this episode by becoming a Major Spoilers Patron at http://patreon.com/MajorSpoilers. It will help ensure Munchkin Land continues far into the future! Join our Discord server and chat with fellow Spoilerites! (https://discord.gg/jWF9BbF) Contact us at podcast@majorspoilers.com NEWS SDJ and KDJ were announced last week 2025 Spiel des Jahres Bomb Busters Flip 7 Krakel Orakel 2025 Kennerspiel des Jahres Endeavor:Deep Sea Faraway Looot Fresh off that KDJ nomination for Endeavor:Deep Sea,  Burt Island games announced a KS will be coming soon for an expansion Endeavor Deep Sea:Uncharted Waters Arcane Wonders will release a “Duel” version of Aquatica called Aquatica Duellum, July ‘25 $45 After a recent KS success Leder Games announced they will release their 5th (?) expansion for Root called Root: The Homeland expansionin Q4 2025 (Possibly Gen Con copies and looks to be 50-60$) Atom Spotlight 2 more great people/channels I got to spend some quality time with in St. Louis in March at ATOM 25. Tabletop Bellhop -- Moe and his lovely wife Deanna have been doing this very insightful channel/podcast/reviews/demos for a long time Laura from Obsessed with Board Games is another one of those great fun follows on Instagram as she does a great job showing new board games and giving a unique insight into them. Digital BG News Dire Wolf digital has released an expansion pack for Clank! On Steam called Clank! Sunken treasures (8.99) Crowdfunding Battle Monsters: Godzilla x Kong ReWild:South America Catch 33: Dexterity/Flicking game Gamefound Trismegistus: Special Ed

Dan Patriss is here to share the latest news from the board game world! Subscribe to the Major Spoilers Podcast Network Master Feed! Major Spoilers Podcast Network Master Feed RSS Feed Show your thanks to Major Spoilers for this episode by becoming a Major Spoilers Patron at http://patreon.com/MajorSpoilers. It will help ensure Munchkin Land continues far into the future! Join our Discord server and chat with fellow Spoilerites! (https://discord.gg/jWF9BbF) Contact us at podcast@majorspoilers.com NEWS SDJ and KDJ were announced last week 2025 Spiel des Jahres Bomb Busters Flip 7 Krakel Orakel 2025 Kennerspiel des Jahres Endeavor:Deep Sea Faraway Looot Fresh off that KDJ nomination for Endeavor:Deep Sea,  Burt Island games announced a KS will be coming soon for an expansion Endeavor Deep Sea:Uncharted Waters Arcane Wonders will release a “Duel” version of Aquatica called Aquatica Duellum, July ‘25 $45 After a recent KS success Leder Games announced they will release their 5th (?) expansion for Root called Root: The Homeland expansionin Q4 2025 (Possibly Gen Con copies and looks to be 50-60$) Atom Spotlight 2 more great people/channels I got to spend some quality time with in St. Louis in March at ATOM 25. Tabletop Bellhop -- Moe and his lovely wife Deanna have been doing this very insightful channel/podcast/reviews/demos for a long time Laura from Obsessed with Board Games is another one of those great fun follows on Instagram as she does a great job showing new board games and giving a unique insight into them. Digital BG News Dire Wolf digital has released an expansion pack for Clank! On Steam called Clank! Sunken treasures (8.99) Crowdfunding Battle Monsters: Godzilla x Kong ReWild:South America Catch 33: Dexterity/Flicking game Gamefound Trismegistus: Special Ed

Neste episódio do Vamos de Vendas, exploramos uma abordagem estratégica que tem redefinido o crescimento de empresas B2B: a transformação de negócios em ecossistemas de parcerias. Para essa conversa, recebemos Nara Vaz Guimarães, empresária, investidora, mentora Endeavor e autora do best-seller Ecossistema de Parceiros.

Bozoma Saint John has one of the most impressive résumés of all time. She's led marketing efforts at nearly every major company, including Netflix, Apple, Uber, PepsiCo, and Endeavor. In addition to her illustrious career as a marketing executive, she's also the founder and CEO of the wig company Eve by Boz, the author of the best-selling book The Urgent Life, and a recent addition to the cast of the Real Housewives of Beverly Hills. On this episode, she discusses her perspective on style—from growing up with a mother who sewed her a custom prom dress to why she decided to exclusively wear clothing from Black designers on this season of RHOBH. She also dives into how it wasn't until she began bringing her authentic self to work that she was able to step into her power and negotiate salaries like a badass.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week Julius tells us about a game as big as a school bus!  Endeavor is a game about exploring the world's oceans solo, cooperatively or competitively.  It's a big game that sounds like lots of fun and very thematic. Endeavor: Deep Sea (BGG)

Focus: The message of Jesus' birth is joyous news that frees us and is available to everyone. It is shared by all because such joy cannot be contained—it overflows! Luke 2:8-20

Vabo é engenheiro de formação, professor por vocação e empreendedor por missão. Fundador da Vabo23 Educação, é referência nacional no desenvolvimento de habilidades pessoais (People Skills), tema que aborda em sua palestra no TEDx e no livro “Falar em público é para você!”. Realiza imersões em gestão de pessoas ao lado de Bernardinho e Ricardo Basaglia, além de atuar como conselheiro e mentor em diversas organizações, incluindo a Endeavor. Co-fundou a startup Sieve Group (vendida para a B2W) e integrou a liderança da Stone até o IPO. Possui formação executiva pela Harvard Business School (OPM), mestrado pelo COPPEAD/UFRJ e graduação em Engenharia de Produção pela PUC-Rio. É também host do VABOcast, e seu propósito é transformar pessoas por meio da educação e do empreendedorismo.Temas:00:00 - Intro02:54 - O Desafio De Ser Empreendedor Na Prática10:15 - Da Engenharia À Criação De Uma Startup De Sucesso18:40 - Construindo Um Time Campeão E A Cultura De Alta Performance25:12 - O Papel Do Autoconhecimento Na Liderança32:00 - Da Mentoria À Transformação Pessoal41:30 - Como A Cultura Se Torna A Vantagem Competitiva Real50:20 - A Evolução Do Empreendedor Para Líder1:02:11 - Presença, Autogestão E Relações Humanas1:15:50 - Refletindo Sobre Propósito, Sucesso E Desenvolvimento Contínuo1:29:30 - Encerramento Com Lições De Liderança E TransformaçãoVabo:https://www.instagram.com/vabo23/Youtube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/excepcionaispodcast⁠⁠Siga:Marcelo Toledo: https://instagram.com/marcelotoledoInstagram: https://instagram.com/excepcionaispodcastTikTok: https://tiktok.com/@excepcionaispodcastPatrocinador:Remessa Online - Envie e receba dinheiro do exterior com taxas mais baixas e sem burocracia.https://www.remessaonline.com.br/?utm_medium=display&utm_source=Excepcionais&utm_campaign=RM_Podcast_Excepcionais_Awareness-2025

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including Real American Wrestling, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Get 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Sun Tzu was a Chinese general, military strategist, writer, and philosopher who lived in the Eastern Zhou period of ancient China. Sun Tzu stresses the importance of knowing one's own strengths and weaknesses, as well as those of the enemy, to gain a strategic advantage.  Avoiding Unnecessary Conflict: A core principle is to avoid battle whenever possible, seeking to subdue the enemy through diplomacy or other means before resorting to direct confrontation.   • Psychological Warfare:  Involves manipulating the enemy's perception and actions, not engaging in personal attacks or pettiness.  I am NOT a communist sympathizer, but China got the scratch to be about that life… ***China seems to think the US wants the smoke, so China is like... bring it. I hope it is true that while they leave the MAGA trade negotiators on read, China is playing Obama speeches…I want this to be true #pettylujah Ms. Tina Knowles Lives Woke... From Weeks Island, LA with Love Ms. Tina K. 432 pages of T—still elegant proud not stooped or bent…hearing Ms. Tina read her own words still can't replace the actual book which I will be ordering…. Reading the book or listening on Audible...you do need both in your life.... From Weeks Island to Seaside Malibu—The fire that destroyed her  home in Malibu was similar to the fire bombing that propelled her family from Weeks Island, a former plantation/salt mine, to Galveston. Still can be bound and have to be re-educated- Sewing bartered skill but only limited by your own fear, mother life of anxiety/fear rightfully so, but binding that she had to unlearn so much. Possibility to fiercely love a parent, admit that they were wrong in a lot, but still love them. The nuns in charge of the children for decades exacted vengeance and sought to humiliate and shame them out of childhood…I would have snatched that tramp's bonnet like President Biden's mama the first time she threatened or hit my kid…chile. The T-on reality TV and Pop Culture Unless you have personal video of ish being removed and returned from the Black-sonian I'm going to need you to have a seat and shut up co trolling my cortisol so should you   Weird loud white conservative making rules. And a bunch of people climbing out of their families basements and thinking you can talk crazy to people. Have seat. We all should be afraid Is it Mormon Tock or Mom tock…Sister Wives Poly Family ya'll Don't even watch TV dictating my viewing da fuck   Lock up Ky creativity and depravity   Go to your prayer closet and leave me alone #rhoa I am a Reigndrop love Monday Live recaps descent to mean girl…season 7 Porsha a mean girl dragged Kenya friend of… she literally still the same selfish airhead now. Claudia clocked it standing on business Trauma bonding 11 seasons still gutta Shame her into act right does what necessary to elevate her brand Season 7 reunion friend of Season 8 Shade Assasin Kenya deprived of us of good ol fashion Read…Regine perfect HW—Kim Fields(wanted to be regular and she was not)  not so much.  Friend of —Sharee Not even the fun Tee Tee. Porsha and single Shamea caught up in some -ish, Miami Season 9 Apex of Frick and Frack, Phaedra exits to return Season 16. If Phaedra going to be fake, not interested.  Contact Us on: https://linktr.ee/tnfroisreading Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, comments on the show, or suggestions for Far From Beale St additions.  

Today, we are sharing an episode of “What It's Like to Be…” from author Dan Heath.  On the podcast, Dan explores the world of work, one profession at a time, and interviews people who love what they do. He finds out: What does a couples therapist think when a friend asks for relationship advice? Is a Secret Service Agent supposed to pretend like they're not there when they're around the president? What are the 3 clocks that govern the life of a long-haul truck driver? If you've ever met someone whose work you were curious about, and you had 100 nosy questions but were too polite to ask… this is the show for you. In this preview, Dan talks to Dr. Hindatu Mohammed, a veterinarian from Austin. You'll hear about how she calms scared cats with pheromone sprays. How she helps clients make hard health care decisions about their pets. You'll also learn what breed of dog, when having its nails clipped, acts like it's being murdered! You may also pick up a word that you may end up wishing you didn't know: “neuticles.”  You can listen to more episodes of What It's Like to Be at https://link.mgln.ai/nsedanheath. Want more NSE? Join NSE+ Today! Our subscriber only community with bonus episodes designed specifically to help you live a good life, ad-free listening, and early access to tickets to our live shows. Great Feeling Studios, the team behind No Small Endeavor and other award-winning podcasts, helps nonprofits and brands tell stories that inspire action. If your organization has a message that deserves to be heard, start your podcast at helpmemakeapodcast.com. Subscribe to episodes: Apple | Spotify | Amazon | Google | YouTubeFollow Us: Instagram | Twitter | Facebook | YouTubeFollow Lee: Instagram | TwitterJoin our Email List: nosmallendeavor.com See Privacy Policy: Privacy Policy Amazon Affiliate Disclosure: Tokens Media, LLC is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Learn about your ad choices: dovetail.prx.org/ad-choices

Marion Maneker joins Peter for a deep dive into the art fair circuit as it hits a fever pitch this week. Marion unpacks the explosion of events on the calendar, whether demand can keep up with the pace, and why Endeavor's Ari Emmanuel just placed a high-stakes bet on Frieze. Then, he draws the line between fairs and auctions—and why the distinction matters. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Consider a few things that will help us to remedy the pride that grows in us so easily. Endeavor to see yourself as you are, your lowliness and utter helplessness, and to see God as He is in his glory and holiness and power. This is part of what church services are to be about: and why hymns that show forth the honor and majesty and glory of God are so important. At the same time be persuaded of the beauty and comeliness of humility. Seek it out and observe it in others, and note how much better it is to be humble than to be proud. It is the grace that is the very opposite of pride, which is abomination to God and men. Put it on like you put on your clothes. Then consider the examples of proud people in the Bible who were humbled and abased. And finally, simply remember that you have nothing to be proud of because we have nothing that we have not received - everything we have, and every ability we possess was given to us.

In this discourse, we delve into the intricacies of the Meta Liberation Army arc and the Endeavor Agency arc from the illustrious series, My Hero Academia. Our examination reveals the profound moral dilemmas faced by both heroes and villains, particularly emphasizing the motivations and transformations of characters such as Shigaraki and Endeavor. We engage in a critical analysis of how both arcs challenge conventional notions of heroism and villainy, thereby inviting listeners to reflect on the complexities of human nature and societal expectations. Furthermore, we explore the narrative techniques employed by the author to evoke empathy towards characters typically perceived as antagonistic. Through our conversation, we aim to illuminate the thematic richness of these arcs, providing a comprehensive understanding of their significance within the broader context of the series.The recent podcast episode of Systematic Geekology presents an in-depth analysis of the Meta Liberation Army arc and the Endeavor Agency arc from My Hero Academia. Hosts Christian Ashley and Elizabeth Pangalangan Clyde embark on a thoughtful exploration of the intricate narrative developments and character arcs that define this segment of the series. The discussion illuminates the motivations behind the Meta Liberation Army's quest for recognition and respect for those with quirks, a theme that resonates with contemporary societal issues. The hosts meticulously dissect the implications of the characters' actions, particularly examining how their past traumas and societal expectations have shaped their current identities. In parallel, the episode delves into Endeavor's evolution as a character, revealing his struggles with redemption and the weight of his legacy as the number one hero. Christian and Liz provide a nuanced perspective on the familial dynamics at play, especially regarding Todoroki's relationship with his father, which serves as a microcosm for broader themes of forgiveness and personal growth. The hosts emphasize the importance of character backstories, particularly those of Shigaraki and Toga, who are depicted not merely as villains but as products of their circumstances. Through this lens, the discussion encourages listeners to reflect on the nature of villainy and the moral ambiguity that often accompanies the characters' choices. The episode ultimately serves as a rich tapestry of analysis, weaving together themes of identity, morality, and societal structures within the context of My Hero Academia. Christian and Liz's insights foster a deeper understanding of the narrative and its characters, prompting listeners to engage critically with the complexities that define heroism and villainy in this beloved series.Takeaways: In this episode of Systematic Geekology, we delve into the complexities of the Meta Liberation Army arc, exploring the motivations behind the villains' actions and their quest for acceptance in a society that marginalizes individuals with unique quirks. The Endeavor Agency arc presents a critical examination of heroism and personal redemption, particularly focusing on Endeavor's evolving relationship with his children and his attempts to atone for his past misdeeds. We analyze the character development of Twice and Toga, two prominent villains, revealing how their tragic backstories influence their actions and the moral dilemmas they face as they navigate a world that has often rejected them. Christian and Liz discuss the thematic elements of prejudice and societal expectations, utilizing the arcs to highlight how characters like Shigaraki and Redestro challenge the status quo in their respective quests for power and recognition. The podcast emphasizes the importance of understanding the villains' perspectives in My Hero Academia, asserting that their motivations stem from deep-seated trauma and societal neglect, thereby...

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including WWE acquiring Lucha Libre AAA, How did WRESTLEMANIA WEEK deliver with GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Get 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Send us a textEsta semana en el Oso Trava Podcast te comparto en exclusiva todo lo que viene para el Endeavor Cracks Summit presentado por Samsung, el evento de negocios, emprendimiento e inspiración más importante de América Latina.Platico sobre la transformación de la educación, la importancia de rodearte de personas que eleven tus estándares, y cómo momentos de alta presión y conexión real pueden cambiar el rumbo de tu vida y tu negocio. También te adelanto algunos de los speakers que estarán este año: Emilio Azcárraga, Martha Debayle, Miguel Layún, Manuel Arango, Salvador Alva, Terry Gutiérrez (Tesla), y muchos más.Más que conferencias, este será un evento de transformación real y conexiones poderosas. ¡Nos vemos el 27 y 28 de mayo en Expo Santa Fe!Boletos en crackssummit.com.

Best of the underground, week of April 22, 2025: Trouble music. (Note that this episode is maybe terrible, but in a different way than normal.) (All podcasts are on www.hlycrp.com, and you can also follow us on Facebook, Instagram, and Spotify, and Apple Podcasts.)  

Stéphane Timpano is CEO of ASPIRE, the program management and business development arm of the Advanced Technology Research Council located in Abu Dhabi. The ATRC's mission is to build a vibrant research and development ecosystem that supports Abu Dhabi—and the broader UAE—in its transformation into a knowledge-based economy. With nearly 1,000 employees representing over 70 nationalities, the Council is also investing in the next generation of innovators through a wide range of STEM initiatives. ASPIRE drives the Council's programmatic efforts by crowdsourcing top global talent through international competitions and grand challenges. These challenges are designed to tackle real-world problems—everything from global hunger and maritime safety to the future of autonomous mobility—by bringing together experts from academia and industry to co-create cutting-edge solutions. As CEO, Stéphane leads ASPIRE's strategic direction and oversees relationships with key stakeholders and partners. He brings more than 15 years of management consulting experience, including major transformation initiatives at Bain & Company in Dubai and Nigeria. His industry expertise spans telecom, media, tech, private equity, and energy. Before consulting, Stéphane worked in the media industry in South Africa and Italy, gaining valuable experience at Sky Italia News Corporation and IMS. He has also been deeply involved in social impact and economic development projects with organizations such as the World Bank, Gates Foundation, Acumen, and Endeavor. He holds an MBA from SDA Bocconi in Milan and a degree in Business Administration from Aix-Marseille University in France. Recently, more than 2,500 people gathered to watch top autonomous drone racers compete for a $1 million prize pool at the Autonomous Drone Racing Grand Championship in Abu Dhabi.  And in case you were wondering, MavLab, from the Delft University of Technology in the Netherlands, secured victories in three out of four competitions. They clinched the AI Grand Challenge with their drone completing two laps of the 170-metre course in just 17 seconds. MavLab won the world's first AI-only drag race, demonstrating straight-line speed and precision under intense acceleration.  And in a landmark moment, MavLab's autonomous drone defeated three top DCL champion pilots in a head-to-head AI-versus-human showdown. With precision flying, the AI-powered drone edged out its human-piloted rivals in thrilling contests.  In this episode of the Drone Radio Show, Stéphane shares insights into ASPIRE's mission, the rise of autonomous racing challenges, and the broader impact these competitions can have across technology, education, and industry.

Industrial Talk is onsite at Xcelerate 2025 and talking to Tom Wilk, Editor in Chief at Endeavor Business Media about "Emerging Industrial Technology". Scott MacKenzie and Tom Wilk discuss the Xcelerate 2025 conference in Austin, Texas, highlighting the importance of asset management, maintenance, and reliability. Tom shares his experience with Plant Services Magazine and the evolution of the conference, emphasizing the adoption of Fluke's E-Maint system by SKF, which is rolling out to 81 plants. They discuss the benefits of a CMMS for sustaining best practices and the importance of AI and mobile components in modern maintenance. Tom also notes the growing interest among younger workers in professional certifications and the need for universities to adapt to industry changes. Action Items [ ] Reach out to Tom Wilk (T Wilk) at Endeavor B2B.com or on LinkedIn to further discuss the topics covered in the meeting. Outline Introduction and Welcome to Industrial Talk Podcast Speaker 1 introduces Scott MacKenzie as a passionate industry professional dedicated to transferring cutting-edge industry innovations and trends. Scott MacKenzie welcomes listeners to the Industrial Talk Podcast, celebrating industry professionals worldwide. Scott MacKenzie thanks the audience for their support and highlights the importance of innovation, collaboration, and making the world a better place. The podcast is broadcasting from Xcelerate 2025 in Austin, Texas, hosted by Fluke Reliability. Introduction of Tom Wilkes and His Role Scott MacKenzie introduces Tom Wilkes, who has been with Plant Services Magazine for 10 years. Tom Wilkes shares his background, including his role at Plant Services Magazine and his involvement in the Accelerate conference. Tom discusses the evolution of the conference from an EMA user group to a thought leadership event focusing on plant floor operations and best practices. Scott MacKenzie and Tom discuss the importance of connected reliability and the various solutions offered by Fluke Reliability. Customer Success Stories and Implementation of E-Main Tom shares a press briefing from SKF about their successful implementation of E-Main across 81 plants worldwide. The success of E-Main led SKF's management to mandate its use across all plants due to the return on investment and streamlined work processes. Tom highlights the various ways different plants are using E-Main to optimize their maintenance programs and data management. Scott MacKenzie and Tom discuss the sustainability of these solutions and the importance of a CMMS in maintaining best practices and collective memory for the plant. Challenges and Solutions in Reliability and Maintenance Scott MacKenzie and Tom discuss the challenges of finding skilled individuals and the impact of the "silver tsunami" on organizational knowledge. Tom emphasizes the importance of investing in systems like E-Main to reduce the learning curve for new employees and maintain organizational knowledge. The mobile aspect of CMMS systems is highlighted as a key factor in getting buy-in from younger technicians. Scott MacKenzie and Tom discuss the importance of having a system like E-Main to capture and maintain organizational knowledge. Evolution of the Xcelerate Conference and Customer Focus Tom notes the subtle but significant change in the messaging at the Xcelerate conference this year, focusing more on tools already being used rather than future...

Today, we are excited to share Dr. Alexandra's recent interview on the Signal Award-winning podcast No Small Endeavor. Produced by PRX and Great Feeling Studios, the podcast explores what it means to live a good life with the help of courageous and impassioned guests like renowned happiness expert Gretchen Rubin, Hidden Brain podcast host Shankar Vedantam, and New York Times bestselling author Malcolm Gladwell.In this specific episode, host and theologian Lee C. Camp and Dr. Solomon discuss insights from her book, "Loving Bravely,” as well as the secrets to thriving intimacy, mastering the art of apology, and staying truly present with your partner. Not to mention she shares practical tools for navigating the inevitable challenges of long-term love.  Listen to more episodes of No Small Endeavor here: https://lnk.to/D28Fv3

Updated For 2025! This Week In Wrestling History (Season 3 Week 14) covering the period of 4/2 thru 4/8. Running Time: 5 Hours 13 Minutes. This Week In Wrestling History hosted by Don Tony first aired in 2018 and spanned two seasons. After much demand, these retro episodes return REMASTERED and UPDATED FOR 2025. Wrestling history up to and including 2024 has been added! Hundreds of hours of original wrestling clips & stories. Enjoy this deep dive into pro wrestling's awesome history. RUNNING TIME: 5 Hours 13 MinutesHosted by Don Tony SYNOPSIS: S3 E14 (04/02 - 04/08) Audio: Jerry Lawler piledrives and sends Andy Kaufman to the hospital. And the entertainment world buys it hook, line, and sinker. Ken Patera and Masa Saito arrested after brawl with WI Police over McDonalds Hamburgers. Looking back at WrestleMania 2 (1986), V (1989), VIII (1992), IX (1993), XI (1995), 2000 (2000), 21 (2005), 22 (2006), XXV (2009), XXVII (2011), XXIX (2013), XXX (2014), 32 (2016), 33 (2017), 34 (2018), 35 (2019), 38 (2022), 39 (2023), 40 (2024) Looking back at NWA Clash Of The Champions 6: Ragin' Cagin (1989). Looking back at AWA SuperClash IV (1990). Shawn Michaels debuts new Raw talk segment: The Heartbreak Hotel. Memorable Raw Womens Match that rarely gets any mention: Alundra Blayze vs Bull Nakano for WWF Womens Championship. Bertha Faye makes WWF Raw debut. Audio: Ultimate Warrior makes Raw debut and has a memorable exchange with Goldust. Following beatdown by Vader, Yokozuna is carried to the locker room by forklift. Looking back at WCW Spring Stampede (1997). Audio: "Hulk Hogan, we coming for you n*****! Audio: Droz makes ECW debut and is greeted by New Jack, a keyboard, crutch, guitar, and vacuum cleaner. Audio: Rob vs Dam def Bam Bam Bigelow and begins 700 day run as ECW TV Champion. Looking back at WCW Pay-Per-Listen: Malice At The Palace (1998). Looking back at ECW Cyberslam '99 (1999). WCW prepares their hard reboot of product and Nitro (2000). Shawn Michaels comes out of retirement and wins Texas Wrestling Alliance (TWA) Championship. HHG Corporation (ECW) files for bankruptcy. Audio: TNN Censors speak Japan: Tajiri 'breaks up' with Torrie Wilson and get censored. Audio: The Rock's last ever Non-PPV TV match (vs Jeff Hardy, 2003). Audio: The Rock 'challenges' Goldberg. Umaga makes WWF Raw debut and lays out Ric Flair. Kevin Nash returns to WWF TV after nine month absence due to Quad Tear. Roddy Piper returns to WWF TV after seven-year absence and has first 'Pipers Pit' in fourteen years. Audio: Vince McMahon and The Product Of His Semen vs Shawn Michaels and God announced for Backlash PPV. All five members of The Spirit Squad are recognized as WWE Tag Team Champions. Mickie James, complete with blonde hair, cosplays Trish Stratus. Audio: Jack Swagger cashes in MITB Briefcase and wins World Heavyweight Championship. CM Punk attempts to have Darren Young join the Straight Edge Society. Things do happen in 3's. TNA Impact episode holds the goofy TNA Knockouts Lockout Challenge, unprotected chairshots to the head, and Orlando Jordan simulating an ejaculation to his chest. (2010). Wrestlicious fails miserably and closes its doors. WWE signs Dean Ambrose and Becky Lynch. The Rock vs John Cena announced a year before WrestleMania XXVIII. Sin Cara (original) makes WWE Raw debut. Kurt Angle pleads guilty to reckless driving after 03/25/11 DWI incident in North Dakota. Audio: Following a very boring John Cena promo on Raw, Brock Lesnar returns to WWE after eight-year absence and F-5's Cena. Daniel Bryan 'breaks up' with AJ Lee. Scott Steiner goes on Twitter Storm against TNA and Hulk Hogan. Looking back at Ring Of Honor: Supercard Of Honor 2013, 2014, 2022 and 2024  Looking back at NJPW: Invasion Attack (2013, 2014, 2015). Audio: One of the loudest crowd 'pops' in Raw history: Dolph Ziggler cashes in MITB Briefcase and def Alberto Del Rio for WWE World Heavyweight Championship. Audio: Memorable Raw match: Randy Orton vs Sheamus and the bored crowd entertains themselves with creative chants and doing the wave. Ezekiel Jackson leaves WWE following contract expiration. Audio: Paige makes WWE Raw debut and def AJ Lee for the Divas Championship. Eat. Sleep. Conquer The Streak. Cesaro becomes a Paul Heyman Guy. Rusev makes WWE Raw debut. Audio: Coming Soon: Adam Rose, Bo Dallas. Audio: Memorable Daniel Bryan Raw promo and crowd reaction after winning WWE World Heavyweight Championship at WrestleMania. Audio: Ultimate Warrior memorable Raw Promo a day before his untimely death. AJ Lee retires and leaves WWE. King Barrett makes final WWE TV appearance and is kicked out of League Of Nationals. Kurt Angle becomes new Raw General Manager. Finn Balor makes WWE in ring return after 7+ month absence with shoulder injury. Drew McIntyre makes WWE return and debuts for NXT. Audio: After defeating Undertaker at WrestleMania, Roman Reigns proclaims WWE is now his yard. And the fans have a meltdown Audio: Triple H has some fun at Billy Gunn and AEW's expense during 2019 Hall Of Fame Induction of D-Generation X  Bret Hart attacked by a mentally ill spectator during 2019 WWE Hall Of Fame Looking back at Ring Of Honor / NJPW G1 Supercard from Madison Square Garden (2019) Looking back at NXT TakeOver: New York Looking back at NXT Stand And Deliver 2021, 2022 and 2024 Audio: The Shield reunite one last time as Dean Ambrose (Jon Moxley) says Goodbye to WWE Universe  Tessa Blanchard, Jordynne Grace and Drake Wuertz go at it on social media over intergender wrestling Audio: Mark Henry thinks that due to the Pandemic, WWE WrestleMania 36 could attract TWO HUNDRED MILLION viewers! Audio: Roman Reigns surprises young terminally ill fan who couldn't attend WrestleMania 36 due to the pandemic Audio: Triple H addresses AEW/NXT Wednesday Night War: "It's a marathon, not a sprint." Hulk Hogan thinks the Covid-19 Pandemic was sent by God Audio: Tony Khan explains why he gave his approval for Chris Jericho to appear on Steve Austin' Broken Skull Sessions which aired on WWE Network and Peacock Christian Cage makes his AEW in-ring debut Triple H officially leaves his boots in the middle of the ring at WrestleMania 38 and retires from in-ring competition Nash Carter (Zachary Wentz) released by WWE after controversial photos are leaked out by estranged wife, Kimber Lee Corey Graves and Carmella get married Tony Khan claims a paid outside independent study confirmed that most of the anti-AEW haters on social media are 'Bots' Audio: Elias' younger brother Ezekiel makes his WWE debut Veer Mahaan is coming! Edge and Damian Priest form an alliance which lead to the creation of the Judgement Day Brodie King takes a shot at the Judgement Day that didn't sit well with wrestling fans Audio: Brock Lesnar turns on and annihilates Cody Rhodes after agreeing to team up and battle Roman Reigns and Solo Sikoa (RAW after WrestleMania 39) UFC and Vince McMahon announce the sale of WWE to Endeavor Audio: Triple H addresses WWE sale to Endeavor on the RAW after WrestleMania 39 Tessa Blanchard and La Rosa Negra bury the hatchet AEW announces their first ever mass release of roster talent Audio: Ronda Rousey appears on the God awful 'Banfield' news show and alleges a sexually inappropriate incident involving Drew Gulak during a WWE event Audio: Joe Tessitore interviews Paul Heyman about his induction into WWE Hall Of Fame  And much more! RIGHT CLICK AND SAVE to download the AUDIO episode of THIS WEEK IN WRESTLING HISTORY S3 E14 (4/2 – 4/8) CLICK HERE to listen to COMMERCIAL FREE episode of THIS WEEK IN WRESTLING HISTORY S3 E14 (4/2 – 4/8) CLICK HERE to listen to THIS WEEK IN WRESTLING HISTORY S3 E14 (4/2 – 4/8) online CLICK HERE to access previous episodes for all the shows === CELEBRATE 20 YEARS OF DON TONY AND KEVIN CASTLE WITH THE DTKC 20 YEAR ANNIVERSARY SHIRT! CLICK HERE for DTKC Pro Wrestling Tees Store  ==== Remember: DON TONY AND KEVIN CASTLE SHOW streams LIVE every MONDAY NIGHT at 10:45PM after WWE RAW at DTKCDiscord.com. ==== DON TONY AND KEVIN CASTLE *PATREON* AND *YOUTUBE CHANNEL MEMBERSHIPS: You can send additional support for Don Tony And Kevin Castle and help grow the brand, by becoming a member of DT/KC PATREON and/or YOUTUBE CHANNEL MEMBERSHIP FAMILY. Don Tony and Kevin Castle's PATREON has been around for over seven years! You can access all seven years of BONUS CONTENT right now including: Ad-Free episodes of all of Don Tony's weekly shows Retro episodes of The Don Tony And Kevin Castle Show going back as early as 2004 (Retro Episodes added each week!) Weekly Patreon podcasts hosted by Don Tony and Kevin Castle 2000+ hours of Patreon exclusive shows never released publicly! (Over 8 Years of Patreon Exclusive Content!) CLICK HERE to access DT/KC Patreon now! YOUTUBE CHANNEL MEMBERSHIPS: Another option is to become a CHANNEL MEMBER on YouTube. Get exclusive enhanced versions of weekly Don Tony and Kevin Castle Show, access to DT's weekly Patreon show, retro DTKC Show episodes, giveaways and more. CLICK HERE for more details and to join The DT/KC YouTube Channel Member Family! ==== CHECK OUT DON TONY AND KEVIN SHOW CONTENT ACROSS THESE PLATFORMS: CLICK HERE FOR APPLE PODCASTS CLICK HERE FOR SPOTIFY CLICK HERE FOR ANDROID CLICK HERE FOR AMAZON MUSIC CLICK HERE FOR GOOGLE PODCASTS CLICK HERE FOR PANDORA CLICK HERE FOR PODBEAN CLICK HERE FOR IHEARTRADIO CLICK HERE FOR DON TONY AND KEVIN CASTLE SHOW MERCHANDISE! ==== DON TONY AND KEVIN CASTLE: WEEKLY SHOW SCHEDULE (UPDATED: NOVEMBER 2024): DON TONY AND KEVIN CASTLE SHOW: LIVE EVERY MONDAY NIGHT at 10:45PM ET after WWE RAW on DTKCDiscord.com DT VIPATREON: Patreon Exclusive Show hosted by Don Tony LIVE EVERY TUESDAY at 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every WEDNESDAY morning at DonTony.com (and across all audio platforms) THIS WEEK IN WRESTLING HISTORY: Posted every THURSDAY at DonTony.com (and across all audio platforms) CASTLE/KNT CHRONICLES: Patreon Exclusive Show hosted by Kevin Castle and Trez LIVE EVERY THURSDAY 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every FRIDAY morning at DonTony.com (and across all audio platforms) PRO WRESTLING WEEKEND NEWS UPDATE: Posted every SATURDAY at DonTony.com (and across all audio platforms) THE SIT-DOWN w/DON TONY: VIDEO PODCAST hosted by Don Tony LIVE EVERY SUNDAY at 8PM on YouTube (www.YouTube.com/DonTony) WWE/AEW PPV RECAP/REVIEW: (Posted MONDAY NIGHT as part of Don Tony and Kevin Castle Show) ==== SOCIAL MEDIA / WEBSITE / CONTACT INFO: Twitter: https://twitter.com/dontonyd Patreon: https://www.patreon.com/dontony Facebook: https://facebook.com/DTKCShow YouTube: https://www.youtube.com/dontony Website: https://www.wrestling-news.com Email: dontony@dontony.com

 @Brasseriecantillonofficiel @alesmithbrewing @newglarusbrewing @jackalopebrew @barriquebrewing #ValentinesDay #beer #podcast #radioshow Co hosts : Good ol Boy Dave, Good ol' Boy Sparky,  Good ol Boy Mike, Good ol Boy Kendall, and Good ol Gal Julieanna SUDS  Episode – Valentine's Day Beer Love Fest On this special episode of Sips, Suds, and Smokes, we're trading roses and chocolates for something a little more romantic—beer! Join our hosts as they each bring a beer that they would choose for their sweetheart in a delightful bottle share. Expect laughter, lively banter, and a few surprises as they introduce their sweetheart beers and share the stories behind their choices. From funky lambics to rich old ales, we'll explore the flavors that speak the language of love. Plus, find out which beers might just earn a thumbs up in the romance department! Tune in for this heartwarming celebration of beer and love, recorded almost live from the Dude in the Basement Studios! We taste and rate the following beer from 1-5:  KENDALL's PICK7:41      Classic Gueuze (2016) – 5% ABV Brasserie Cantillon Anderlecht, Bruxelles Belgium   SUDS-5 MIKE'S PICK14:43    Private Stock Ale (2016)- 11% ABV AleSmith Brewing Company San Diego, CA SUDS-5 SPARKY'S PICK23:06    Strawberry Rhubarb (bottle vintage 2019) (can vintage 2021) 4% ABV New Glarus Brewing Company New Glarus, WI  SUDS-5 – can is better than bottle DAVE'S PICK37:52    Lovebird – wheat with strawberry and raspberry 4.4% ABV.  Jackalope Brewing Company Nashville, TN  SUDS-2 JULIEANNA'S PICK44:19    Talking Machine – English IPA with First Gold and Endeavor hops.  6% ABV  Barrique Brewing and Blending, Nashville, TN  SUDS-5 BONUS BEER49:03    Serendipity- Wisconsin Ale brewed with Apples, Cranberries, and Cherries- 4% ABV  New Glarus Brewing Company New Glarus, WI  SUDS-5 info@sipssudsandsmokes.com X- @sipssudssmokes IG/FB/Bluesky - @sipssudsandsmokes Sips, Suds, & Smokes® is produced by One Tan Hand Productions using the power of beer, whiskey, and golf.  Available on Apple Podcasts, YouTube Music, Spotify, Pandora, iHeart, and nearly anywhere you can find a podcast.Check out Good ol Boy Dave on 60 Second Reviewshttps://www.instagram.com/goodoleboydave/Kendall is working on his new idea for a bouquet of beers “Love in the Can” as the perfect gift for a lover. His blog is much better than this show: www.beermakesthree.com Enjoying that cool new Outro Music, it's from Woods & Whitehead – Back Roads Download your copy here:https://amzn.to/2XblorcThe easiest way to find this award winning podcast on your phone is ask Alexa, Siri or Google, “Play Podcast , Sips, Suds, & Smokes” Credits:TITLE: Maxwell Swing/ FlapperjackPERFORMED BY: Texas GypsiesCOMPOSED BY: Steven R Curry (BMI)PUBLISHED BY: Alliance AudioSparx (BMI)TITLE: Back RoadsPERFORMED BY: Woods & WhiteheadCOMPOSED BY: Terry WhiteheadPUBLISHED BY: Terry WhiteheadCOURTESY OF: Terry WhiteheadPost production services : Pro Podcast SolutionsAdvertising sales: Contact us directlyContent hosting services:  Earshot, Radio4All, PodBeanProducer: Good ol Gal Julieanna & Good ol Boy DaveExecutive Producer: Good ol Boy Mike

Group Chat News is back with the hottest stories of the week including Dee talks about Ghost and how important A I is for businesses, LeBron goes on Pat McAfee, Steph Curry & Michelle Obama are launching a hydration drink, Speed goes to China, Endeavor officially goes private as Ari Emanuel and Patrick Whitesell change roles, Sources say the details shared by Hegseth in Signal chat were classified as Atlantic publishes additional messages, MTA sees green with congestion pricing, as tolls bring in $100M during first 2 months, Meta plans to charge $14 a month for add free Instagram, and of course everyone's favorite WINNERS LOSERS CONTENT

John Pollock and Brandon Thurston are joined by Sean Ross Sapp of Fightful to discuss the TNA cuts and the lead-up to this year's WrestleMania.They chat about the reaction internally to the TNA cuts including Gail Kim being let go and the state of TNA in the marketplace.Plus, the promotion of WrestleMania 41 as WWE prepares for its major week in Las Vegas.TIME STAMPS:00:00:00 Start00:03:07 Using Signal00:08:23 TNA cuts including Gail Kim00:12:40 Endeavor goes private00:14:52 Orlando seeking grant to bid on WWE & UFC events00:18:06 UFC sets Fight Night gate record00:20:18 SmackDown ratings and its three-hour format00:22:47 AEW Slam Dunk airing after NCAA00:26:53 WWE Raw on Netflix from March 1700:29:33 Sean Ross Sapp from Fightful.com 00:53:32 WWE's YouTube strategy for its video libraries00:56:15 WWE creative pushback 00:59:37 Relationship between match time and match quality RELATED:Endeavor goes private, TKO remains public and unchangedREPORT: Gail Kim among names departing TNA WrestlingOrlando seeking $18 million grant to bid on WWE & UFC eventsAEW Collision “Slam Dunk” Saturday and Sunday, Mar 22 & 23 on TNT: 554,000 viewers; 0.20 P18-49 rating & 584,000; 0.22WWE Raw, Mar 17 on Netflix: 3,100,000 global viewsMusic courtesy: “Panic Beat” by Ben TramerPOST WrestlingSubscribe: https://postwrestling.com/subscribePatreon: http://postwrestlingcafe.comForum: https://forum.postwrestling.comDiscord: https://discord.com/invite/Q795HhRMerch: https://store.postwrestling.comTwitter/Facebook/Instagram/YouTube: @POSTwrestlingBluesky: https://bsky.app/profile/postwrestling.comWrestlenomicsSubscribe: https://wrestlenomics.com/podcast/Patreon: https://patreon.com/wrestlenomicsSubstack: https://wrestlenomics.substack.com/Twitter/Facebook/Instagram/YouTube: @WrestlenomicsBluesky: https://bsky.app/profile/wrestlenomics.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

John Pollock and Wai Ting review WWE Raw from Glasgow, Scotland featuring John Cena & Cody Rhodes appearing and Bron Breakker vs. Penta for the Intercontinental title.Also: Lyra Valkyria defends the Women's Intercontinental title against Raquel Rodriguez, Jey Uso, and a partner take on A-Town Down Under, and Dragon Lee faces Chad Gable.The XL Edition continues at POSTwrestlingCafe.com with News of the Day and Feedback, ad-free. Today's stories:Bill Mercer passes away at 99Independent wrestler Artist Artest dies Janice Carter passes Cain Velasquez sentenced Endeavor goes privateROH Supercard of Honor Gable Steveson loses in NCAA heavyweight finalNatural Disasters in the WWE Hall of Fame NXT & AEW Dynamite lineups F1 Chinese Grand Prix thoughtsPOST Wrestling Café Schedule:Tuesday: Book Club - The Queen of the Ring by Jeff LeenThursday: MCU L8R - Daredevil Ep. 5 & 6 Friday: Luna Vachon documentary review Saturday: Collision Course FREE Shows:Tuesday: upNXTWednesday: Pollock & Thurston  Wednesday: Rewind-A-Dynamite (XL in the Café)Thursday: The Wellness PolicyFriday: Rewind-A-SmackDown (XL in the Café)Photo Courtesy: WWE Rewind-A-Raw Theme by Colby John: https://soundcloud.com/colbyjohnBluesky: https://bsky.app/profile/postwrestling.comX: http://www.twitter.com/POSTwrestlingInstagram: http://www.instagram.com/POSTwrestlingFacebook: http://www.facebook.com/POSTwrestlingYouTube: http://www.youtube.com/POSTwrestlingSubscribe: https://postwrestling.com/subscribePatreon: http://postwrestlingcafe.comForum: https://forum.postwrestling.comDiscord: https://postwrestling.com/discordMerch: https://Chopped-Tees.com/POSTwrestlingAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This episode (aka "Napa Act 1") was recorded live in 2022 at the Blue Note Jazz Festival.“Art is the perfect place to talk it out–in fact, maybe the last place.” The crew reflects on how nuance and purpose is lost in a culture that favors judgment over debate.Executive Produced by Talib Kweli, yasiin bey, Dave Chappelle, Noah Gersh, Jamie Schefman, Nick Panama, and Kenzi WilburProduced, Edited, and Composed by Noah Gersh and Jamie Schefman for SALTProduction Manager: Liz LeMayProduction Coordinator: Diana Chammas Live Engineering by: Mike Brown Mixed by: Mario Borgatta & Jordan GalvanPodcast Artwork: Leeann SheelyStill Photography: Mathieu BittonThe Midnight Miracle is a Luminary Original Podcast in partnership with Pilot Boy Productions and SALT.Special thanks to Ted Williams, Paul Adongo, Cipriano Beredo, Elaine Chappelle, Ivy Davy, Rikki Hughes, Sina Sadighi, Deborah Mannis-Gardner, Nicolle Johnson, Donna Dragotta, Carla Sims, Pete Amaro, Clint Balcom, Jennifer Branigan, Taylor Dalton, Miles Hodges, Zainab Khan, Christopher Landry, Coral Lee, Jayme Lynes, Mykola Logvynenko, Rishi Malhotra, Mohan Nerkar, Brian Parsons, Lauren Perkins, Kyle Ranson-Walsh, Matt Sacks, Betsy Santoyo, Lisa Schrader, Akhila Shankar, Leeann Sheely, and Mark Silverstein.Photography made available courtesy of Pilot Boy Productions, Inc. Copyright © 2022 by Pilot Boy Productions, Inc., all rights reserved.